Financings in Brief: Imagyn Medical:
This article was originally published in The Gray Sheet
Imagyn Medical: Adopts shareholder rights plan "to assure that the company's stockholders receive fair and equal treatment in the event of any proposed takeover of the company, and to guard against partial tender offers and other abusive tactics to gain control of Imagyn without paying all stockholders the fair value of their shares." Rights become exercisable following the acquisition of 15% or more of Imagyn's common stock...
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.